Related Experiment Videos
Photodynamic therapy of eye diseases
1Tufts University School of Medicine, Department of Vitreoretinal Surgery, New England Eye Center, 750 Washington Street, Box 450, Boston, MA 02111, USA.
Journal of Ophthalmic Nursing & Technology
|March 16, 2001
Summary
Photodynamic therapy (PDT) shows promise for treating eye conditions. New photosensitizers improve PDT
Area of Science:
- Ophthalmology
- Oncology
- Photochemistry
Background:
- Photodynamic therapy (PDT) is established for cutaneous cancers.
- Advancements in photosensitizers offer improved absorption and tolerance.
- PDT utilizes targeted light activation for selective tissue damage.
Purpose of the Study:
- Investigate the application of novel photosensitizers in ophthalmology.
- Explore PDT for treating ocular tumors and neovascularization.
- Assess PDT's potential for ciliary body ablation.
Main Methods:
- Utilizing second-generation photosensitizers with enhanced properties.
- Employing low-energy directed light for focal activation.
- Targeting photosensitizer sequestration within ocular tissues.
Main Results:
- Visudyne, an FDA-approved PDT drug, is used for subfoveal choroidal neovascularization.
- Numerous patients have been successfully treated with Visudyne.
- PDT demonstrates potential for various ophthalmic applications.
Conclusions:
- Second-generation photosensitizers are expanding PDT's role in ophthalmology.
- PDT offers a targeted approach for treating ocular diseases.
- The efficacy of PDT is supported by existing FDA approvals and patient treatments.